pioglitazone has been researched along with Chronic Lung Injury in 5 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Since PPAR-γ agonists have been demonstrated to promote neonatal lung maturation and injury repair, we hypothesized that a formulation of a PPAR-γ agonist, pioglitazone (PGZ) and a synthetic lung surfactant (a surfactant protein B peptide mimic, B-YL) combined would stimulate lung maturation and block hyperoxia-induced neonatal lung injury more effectively than either modality alone." | 7.88 | A Combination of the Aerosolized PPAR-γ Agonist Pioglitazone and a Synthetic Surfactant Protein B Peptide Mimic Prevents Hyperoxia-Induced Neonatal Lung Injury in Rats. ( Lee, C; Rehan, VK; Sakurai, R; Shen, H; Walther, FJ; Waring, AJ, 2018) |
| "Hyperoxia-induced lung injury is characterized by acute alveolar injury, disrupted epithelial-mesenchymal signaling, oxidative stress, and surfactant dysfunction, yet currently, there is no effective treatment." | 5.91 | Combination of pioglitazone, a PPARγ agonist, and synthetic surfactant B-YL prevents hyperoxia-induced lung injury in adult mice lung explants. ( Chuang, TD; Kurihara, C; Rehan, VK; Sakurai, R; Walther, FJ; Waring, AJ, 2023) |
| "Since PPAR-γ agonists have been demonstrated to promote neonatal lung maturation and injury repair, we hypothesized that a formulation of a PPAR-γ agonist, pioglitazone (PGZ) and a synthetic lung surfactant (a surfactant protein B peptide mimic, B-YL) combined would stimulate lung maturation and block hyperoxia-induced neonatal lung injury more effectively than either modality alone." | 3.88 | A Combination of the Aerosolized PPAR-γ Agonist Pioglitazone and a Synthetic Surfactant Protein B Peptide Mimic Prevents Hyperoxia-Induced Neonatal Lung Injury in Rats. ( Lee, C; Rehan, VK; Sakurai, R; Shen, H; Walther, FJ; Waring, AJ, 2018) |
| "Hyperoxia-induced lung injury is characterized by acute alveolar injury, disrupted epithelial-mesenchymal signaling, oxidative stress, and surfactant dysfunction, yet currently, there is no effective treatment." | 1.91 | Combination of pioglitazone, a PPARγ agonist, and synthetic surfactant B-YL prevents hyperoxia-induced lung injury in adult mice lung explants. ( Chuang, TD; Kurihara, C; Rehan, VK; Sakurai, R; Walther, FJ; Waring, AJ, 2023) |
| "Carvacrol treatment improved inhaled PQ-induced lug injury similar to the effects of dexamethasone." | 1.62 | Carvacrol and PPARγ agonist, pioglitazone, affects inhaled paraquat-induced lung injury in rats. ( Amin, F; Boskabady, MH; Kazerani, HR; Memarzia, A; Rad, HK, 2021) |
| "Although pioglitazone-induced lung injury is very rare, clinicians should keep it in mind when pioglitazone is used." | 1.43 | Pioglitazone-induced Pulmonary Injury in a Very Elderly Patient. ( Fujihara, K; Isono, M; Kagohashi, K; Katayama, K; Kumagai, R; Ohara, G; Satoh, H; Yagyu, H, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kurihara, C | 1 |
| Sakurai, R | 3 |
| Chuang, TD | 1 |
| Waring, AJ | 2 |
| Walther, FJ | 2 |
| Rehan, VK | 3 |
| Amin, F | 1 |
| Memarzia, A | 1 |
| Rad, HK | 1 |
| Kazerani, HR | 1 |
| Boskabady, MH | 1 |
| Lee, C | 1 |
| Shen, H | 1 |
| Morales, E | 1 |
| Husain, S | 1 |
| Paek, D | 1 |
| Gong, M | 1 |
| Ibe, B | 1 |
| Li, Y | 1 |
| Husain, M | 1 |
| Torday, JS | 1 |
| Katayama, K | 1 |
| Kumagai, R | 1 |
| Isono, M | 1 |
| Fujihara, K | 1 |
| Yagyu, H | 1 |
| Ohara, G | 1 |
| Kagohashi, K | 1 |
| Satoh, H | 1 |
5 other studies available for pioglitazone and Chronic Lung Injury
| Article | Year |
|---|---|
Combination of pioglitazone, a PPARγ agonist, and synthetic surfactant B-YL prevents hyperoxia-induced lung injury in adult mice lung explants.
Topics: Animals; Hyperoxia; Lung; Lung Injury; Mice; Pioglitazone; PPAR gamma; PPAR-gamma Agonists; Surface- | 2023 |
Carvacrol and PPARγ agonist, pioglitazone, affects inhaled paraquat-induced lung injury in rats.
Topics: Animals; Case-Control Studies; Cymenes; Dexamethasone; Disease Models, Animal; Drug Synergism; Gene | 2021 |
A Combination of the Aerosolized PPAR-γ Agonist Pioglitazone and a Synthetic Surfactant Protein B Peptide Mimic Prevents Hyperoxia-Induced Neonatal Lung Injury in Rats.
Topics: Administration, Inhalation; Animals; Animals, Newborn; Biomimetic Materials; Cell Differentiation; F | 2018 |
Nebulized PPARγ agonists: a novel approach to augment neonatal lung maturation and injury repair in rats.
Topics: Administration, Inhalation; Animals; Animals, Newborn; Bronchoalveolar Lavage; Cell Differentiation; | 2014 |
Pioglitazone-induced Pulmonary Injury in a Very Elderly Patient.
Topics: Adrenal Cortex Hormones; Aged, 80 and over; Diabetes Mellitus, Type 2; Dyspnea; Female; Humans; Lung | 2016 |